Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label Phase I/II Trial to Evaluate the Safety and Activity of CPC-P501 Protein Formulated With the Adjuvant AS15 as First-line Treatment in Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA
Conditions
Interventions
P501-AS15 vaccine
Locations
8
Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Turnhout, Belgium
GSK Investigational Site
Auxerre, France
GSK Investigational Site
Besançon, France
GSK Investigational Site
Paris, France
Start Date
March 1, 2005
Primary Completion Date
November 7, 2006
Completion Date
November 7, 2006
Last Updated
June 2, 2017
NCT04249947
NCT01337258
NCT01209988
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions